Press Releases

Biothera Pharmaceuticals Presents Clinical Data from Phase 2 Study Evaluating the Combination of Imprime PGG and Merck’s KEYTRUDA in Triple Negative Breast Cancer at 2019 ASCO Annual Meeting

Imprime PGG is a dectin receptor agonist that triggers anti-cancer immune responses IMPRIME 1 study enrolled 44 previously treated, metastatic triple negative breast cancer (TNBC) patients 15.9% Overall Response Rate (Three previous TNBC clinical studies with checkpoint inhibitor (CPI) monotherapies generated response rates of 5% to 6%) 25% Disease Control Rate >24 weeks 13.7 months median Overall Survival, with 64.2% patient survival at 12 months...

Read More


Biothera Pharmaceuticals to Present Clinical Data from Phase 2 Triple Negative Breast Cancer Study at ASCO 2019 Annual Meeting

Study Evaluating Combination of Biothera’s Imprime PGG and Merck’s KEYTRUDA® EAGAN, MN — May 16, 2019 — Biothera Pharmaceuticals, Inc., which is developing a dectin receptor agonist drug known as Imprime PGG, announced today that it will present primary clinical data from its phase 2 study in chemo-refractory metastatic triple negative breast cancer at the American Society of Clinical Oncology (ASCO) 2019 annual meeting, May...

Read More


Biothera Pharmaceuticals to Present at the Needham & Company Healthcare Conference

EAGAN, MN — April 2, 2019 — Biothera Pharmaceuticals, Inc. today announced that Jeremy Graff, Ph.D., President and Chief Scientific Officer, and Andrew D. C. LaFrence, Senior Vice President and Chief Financial Officer, will present at the Needham & Company 18th Annual Healthcare Conference on April 9 at 3:10 PM Eastern Time in New York City. About Biothera Pharmaceuticals, Inc. Biothera Pharmaceuticals is a privately...

Read More


Biothera Pharmaceuticals to Participate in Webinar on Utilizing Innate Immune Mechanisms to Trigger Anti-Cancer Responses

EAGAN, MN — March 25, 2019 — Biothera Pharmaceuticals, Inc. President and Chief Scientific Officer Jeremy Graff, Ph.D., will participate in a webinar tomorrow on the development of therapies targeting innate immune mechanisms to overcome cancer defenses and initiate anti-tumor responses.  The Scientist magazine will host the webinar, “Keeping Cancer in Check: Innate Immunity and Checkpoint Inhibitors,” from 2:30-4:00pm Eastern Time.  Registration is free. In...

Read More


Biothera Pharmaceuticals Announces Management Changes

EAGAN, MN — December 13, 2018 — Biothera Pharmaceuticals, Inc. announced today that Chief Executive Officer Barry Labinger has resigned to pursue another opportunity, effectively immediately.  Biothera Holding Corp. Chairman Richard Mueller has been appointed acting CEO.  Jeremy Graff, Ph.D., has been named President in addition to his position as Chief Scientific Officer.  Dr. Graff will have responsibility for Research, Clinical Operations and Manufacturing.  Since...

Read More


Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

Collaboration will evaluate the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab in a Phase 2 neoadjuvant study for patients with head and neck cancer EAGAN, MN — September 5, 2018 — Biothera Pharmaceuticals, Inc. announced today a clinical collaboration with AstraZeneca to evaluate whether the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab (IMFINZI®) can decrease tumor volume in patients with primary untreated locally...

Read More


Biothera Pharmaceuticals Appoints Andrew D.C. LaFrence Chief Financial Officer

EAGAN, MN — May 16, 2018 — Biothera Pharmaceuticals, Inc., announced the appointment of Andrew D.C. LaFrence, CPA as Senior Vice President and Chief Financial Officer, effective May 29.  Biothera Pharmaceuticals is a clinical stage immuno-oncology company developing a novel immunotherapy in combination with immune checkpoint inhibitors for multiple types of cancer. Mr. LaFrence has 34 years of accounting and finance experience, including executive management...

Read More


Biothera Pharmaceuticals Presents Translational Data from Ongoing Clinical Trials Showing Imprime PGG in Combination with Merck’s KEYTRUDA® (pembrolizumab) Drives Innate and Adaptive Immune Responses in Tumors

EAGAN, MN — April 16, 2018 — Biothera Pharmaceuticals, Inc. today announced the presentation of new translational data from ongoing phase 2 clinical trials combining Biothera’s Imprime PGG with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck (known as MSD outside the United States and Canada).  These data provide the first evidence in human clinical trials that Imprime PGG-based therapy can activate the immune system...

Read More


Preclinical Data Showing Synergy of Biothera Pharmaceuticals’ Imprime PGG and a CD40 Agonist in a Pancreatic Cancer Model Presented at Keystone Symposia

EAGAN, MN — March 26, 2018 — Biothera Pharmaceuticals, Inc. and the Abramson Cancer Center of the University of Pennsylvania announced today the presentation of new preclinical data demonstrating the combination of Imprime PGG and a CD40 agonist antibody stimulated T cell-dependent anti-tumor activity in a pancreatic cancer model.  The data were presented at the ongoing Keystone Symposia Conference – Cancer Immunotherapy: Combinations in Montreal,...

Read More


Biothera Pharmaceuticals Commences Phase 2 Head and Neck Cancer Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)

Study Is Second Clinical Research Collaboration with Merck EAGAN, MN — February 6, 2018 — Biothera Pharmaceuticals, Inc. announced today that patient treatment has commenced in its Phase 2 clinical study in squamous cell carcinoma of the head and neck (SCCHN).  The research collaboration with Merck (known as MSD outside the United States and Canada) will evaluate Biothera’s Imprime PGG in combination with KEYTRUDA® (pembrolizumab),...

Read More



Page 1 of 3123